FOXA2 and prostate adenocarcinoma: Concordant with the clinical expression profile of LINC00261, FOXA2 expression was significantly elevated in NEPC PDX models (Fig. 4B) and NEPC patient tumors (Fig. 4C) compared with prostate adenocarcinoma.